Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling
Qian Zhang, Tenagne D. Challa, Robert Augustin, et al.
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 833-844.e5
Open Access | Times Cited: 192

Showing 1-25 of 192 citing articles:

Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Juan P. Frías, Melanie J. Davies, Julio Rosenstock, et al.
New England Journal of Medicine (2021) Vol. 385, Iss. 6, pp. 503-515
Open Access | Times Cited: 1117
Anti-obesity drug discovery: advances and challenges
Timo D. Müller, Matthias Blüher, Matthias H. Tschöp, et al.
Nature Reviews Drug Discovery (2021) Vol. 21, Iss. 3, pp. 201-223
Open Access | Times Cited: 688
Pharmacotherapy of obesity: an update on the available medications and drugs under investigation
Marlene Chakhtoura, Rachelle Haber, Malak Ghezzawi, et al.
EClinicalMedicine (2023) Vol. 58, pp. 101882-101882
Open Access | Times Cited: 253
The evolving story of incretins (GIP and GLP‐1) in metabolic and cardiovascular disease: A pathophysiological update
Michael A. Nauck, Daniel R. Quast, Jakob Wefers, et al.
Diabetes Obesity and Metabolism (2021) Vol. 23, Iss. S3, pp. 5-29
Closed Access | Times Cited: 219
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes
Michael A. Nauck, Jakob Wefers, Juris J. Meier
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 8, pp. 525-544
Closed Access | Times Cited: 203
Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regrading glycaemic control and body weight reduction
Michael A. Nauck, David A. D‘Alessio
Cardiovascular Diabetology (2022) Vol. 21, Iss. 1
Open Access | Times Cited: 175
Role of the gut–brain axis in energy and glucose metabolism
Hallie Wachsmuth, Savanna N. Weninger, Frank A. Duca
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 4, pp. 377-392
Open Access | Times Cited: 129
Beyond the pancreas: contrasting cardiometabolic actions of GIP and GLP1
Rola Hammoud, Daniel J. Drucker
Nature Reviews Endocrinology (2022) Vol. 19, Iss. 4, pp. 201-216
Closed Access | Times Cited: 127
Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist
Martin Bossart, Michael Wagner, Ralf Elvert, et al.
Cell Metabolism (2021) Vol. 34, Iss. 1, pp. 59-74.e10
Open Access | Times Cited: 124
The expanding incretin universe: from basic biology to clinical translation
Daniel J. Drucker, Jens J. Holst
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1765-1779
Open Access | Times Cited: 117
GIP Receptor Agonism Attenuates GLP-1 Receptor Agonist–Induced Nausea and Emesis in Preclinical Models
Tito Borner, Caroline E. Geisler, Samantha M. Fortin, et al.
Diabetes (2021) Vol. 70, Iss. 11, pp. 2545-2553
Open Access | Times Cited: 107
Recent Advances in Incretin-Based Pharmacotherapies for the Treatment of Obesity and Diabetes
Qiming Tan, Seun Akindehin, Camila E. Orsso, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 104
What is the pipeline for future medications for obesity?
Eka Melson, Uzma Ashraf, Dimitris Papamargaritis, et al.
International Journal of Obesity (2024)
Open Access | Times Cited: 104
Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Patrick J. Knerr, Stephanie A. Mowery, Jonathan D. Douros, et al.
Molecular Metabolism (2022) Vol. 63, pp. 101533-101533
Open Access | Times Cited: 86
Incretin hormones and type 2 diabetes
Michael A. Nauck, Timo D. Müller
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1780-1795
Open Access | Times Cited: 78
A GIPR antagonist conjugated to GLP-1 analogues promotes weight loss with improved metabolic parameters in preclinical and phase 1 settings
Murielle M. Véniant, Shu-Chen Lu, Larissa Atangan, et al.
Nature Metabolism (2024) Vol. 6, Iss. 2, pp. 290-303
Open Access | Times Cited: 67
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
Kimberley El, Jonathan D. Douros, Francis S. Willard, et al.
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 945-954
Open Access | Times Cited: 64
Efficacy and Safety of Tirzepatide in Type 2 Diabetes and Obesity Management
Rachel Sinha, Dimitris Papamargaritis, Jack A. Sargeant, et al.
Journal of Obesity & Metabolic Syndrome (2023) Vol. 32, Iss. 1, pp. 25-45
Open Access | Times Cited: 61
Gut hormone co-agonists for the treatment of obesity: from bench to bedside
Rubén Nogueiras, Michael A. Nauck, Matthias H. Tschöp
Nature Metabolism (2023) Vol. 5, Iss. 6, pp. 933-944
Closed Access | Times Cited: 57
GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications
Jonathan E. Campbell, Timo D. Müller, Brian Finan, et al.
Cell Metabolism (2023) Vol. 35, Iss. 9, pp. 1519-1529
Open Access | Times Cited: 57
Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy
Matthias H. Tschöp, Rubén Nogueiras, Bo Åhrén
Diabetologia (2023) Vol. 66, Iss. 10, pp. 1796-1808
Open Access | Times Cited: 51
Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?
Simon Kloock, Christian G. Ziegler, Ulrich Dischinger
Pharmacology & Therapeutics (2023) Vol. 251, pp. 108549-108549
Open Access | Times Cited: 49
GLP-1-directed NMDA receptor antagonism for obesity treatment
Jonas Petersen, Mette Q. Ludwig, Vaida Juozaityte, et al.
Nature (2024) Vol. 629, Iss. 8014, pp. 1133-1141
Open Access | Times Cited: 38
Diabetes mellitus—Progress and opportunities in the evolving epidemic
E. Dale Abel, Anna L. Gloyn, Carmella Evans‐Molina, et al.
Cell (2024) Vol. 187, Iss. 15, pp. 3789-3820
Closed Access | Times Cited: 33
Obesity and the kidney: mechanistic links and therapeutic advances
Kevin Yau, Rachel Kuah, David Z.I. Cherney, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 6, pp. 321-335
Closed Access | Times Cited: 31
Page 1 - Next Page

Scroll to top